Integra LifeSciences reported a slight revenue decline in Q4 2025, impacted by remediation efforts in its Tissue Technologies segment, while showing organic growth in its Codman Specialty Surgical business. The company is undergoing a transformation plan to improve long-term margins and operational accountability.

Integra LifeSciences delivered a strong third quarter in 2025 with total revenues of $402.1 million, marking a 5.6% increase year-over-year. The company achieved significant profitability improvements, with adjusted EPS rising to $0.54 from $0.41 in the prior year, and adjusted EBITDA reaching $78.5 million. Despite some supply interruptions, demand remained healthy across its portfolio, and strategic initiatives to strengthen the supply chain and quality management system are progressing.

Integra LifeSciences reported second-quarter 2025 revenues of $415.6 million, a slight decrease of 0.6% year-over-year. GAAP EPS was significantly impacted by a $511 million goodwill impairment charge, resulting in a net loss of $(484.1) million and diluted EPS of $(6.31). However, adjusted EPS was $0.45, meeting the top end of their guidance. The company highlighted strong demand for neurosurgery and tissue technology products and progress on their Compliance Master Plan.

Integra LifeSciences reported total revenues of $382.7 million in the first quarter of 2025, a 3.7% increase year-over-year. GAAP net loss was $(25.3) million, or $(0.33) per diluted share, while adjusted net income was $31.7 million, or $0.41 per diluted share. The company is reaffirming its full-year revenue guidance but updating adjusted EPS guidance due to new tariffs.

Integra LifeSciences reported a revenue of $442.6 million for Q4 2024, an 11.5% increase compared to Q4 2023. GAAP earnings per diluted share were $0.25, while adjusted earnings per diluted share were $0.97.

Integra LifeSciences reported a slight decrease in third-quarter revenue and a significant drop in GAAP and adjusted earnings per share compared to the previous year. The company is progressing with its compliance master plan and announced Mojdeh Poul as the next president and CEO.

Integra LifeSciences reported a 9.7% increase in second-quarter revenues to $418.2 million, with a GAAP net loss of $(12.4) million, or $(0.16) per diluted share. Adjusted earnings per diluted share were $0.63. The company is updating its full-year revenue guidance to $1.609 billion to $1.629 billion and adjusted EPS guidance to $2.41 to $2.57.

Integra LifeSciences reported first-quarter revenues of $368.9 million, a 3.1% decrease compared to the prior year. GAAP earnings per diluted share were $(0.04), while adjusted earnings per diluted share were $0.55. The company updated its full-year 2024 revenue guidance to $1.672 to $1.687 billion, including the impact of the Acclarent acquisition.

Integra LifeSciences reported Q4 2023 revenues of $397.0 million, a decrease of 0.2% compared to Q4 2022. GAAP earnings per diluted share were $0.25, and adjusted earnings per diluted share were $0.89. The company is focusing on the Boston relaunch, global CereLink relaunch, SIA acquisition integration, and international portfolio expansion.

Integra LifeSciences reported Q3 2023 revenues of $382.4 million, a decrease of 0.7% on a reported basis and 0.4% on an organic basis compared to the prior year. GAAP earnings per diluted share were $0.24, while adjusted earnings per diluted share were $0.76. The company is updating its full-year 2023 revenue and adjusted earnings per share guidance to a range of $1.541 billion to $1.547 billion and $3.10 to $3.14 respectively.

Integra LifeSciences reported a decrease in revenue and earnings per share for Q2 2023 compared to the previous year. Total revenues were $381.3 million, a 4.2% decrease, and GAAP earnings per diluted share were $0.05, compared to $0.54 in the prior year. The company is updating its full-year 2023 revenue and adjusted EPS guidance to $1.548 billion to $1.560 billion and $3.10 to $3.18, respectively.

Integra LifeSciences reported a 1.1% increase in first-quarter revenue to $380.8 million, with organic growth of 4.6%. The company reaffirmed its full-year 2023 revenue guidance of $1,602 million to $1,620 million and adjusted EPS guidance of $3.43 to $3.51.

Integra LifeSciences reported Q4 2022 revenues of $398.0 million, a decrease of 1.8% compared to Q4 2021, but an increase of 2.9% on an organic basis. GAAP earnings per diluted share were $0.63, and adjusted earnings per diluted share were $0.94.

Integra LifeSciences reported a slight decrease in total revenues but an increase in organic revenue for Q3 2022. GAAP EPS was $0.60, while adjusted EPS remained flat at $0.86. The company completed the sale of its traditional wound care business and raised its full-year EPS outlook.

Integra LifeSciences reported a 2.0% increase in second-quarter revenues to $398 million, with organic growth of 4.8%. GAAP earnings per diluted share were $0.54, up from $0.41 in the prior year, and adjusted earnings per diluted share were $0.82, compared to $0.79 in the prior year. The company has tightened its full-year 2022 organic growth guidance to 4.0% to 5.2%.

Integra LifeSciences reported a 4.6% increase in revenue to $376.6 million in Q1 2022. GAAP earnings per diluted share were $0.39, while adjusted earnings per diluted share were $0.74. The company raised its full-year 2022 organic growth guidance to a new range of 3.8% to 5.2%.

Integra LifeSciences reported a revenue increase of 4.3% on a reported basis and 8.3% on an organic basis for Q4 2021. GAAP earnings per diluted share were $0.53, while adjusted earnings per diluted share were $0.84, flat compared to Q4 2020.

Integra LifeSciences reported Q3 2021 revenues of $386.9 million, a 4.5% increase on a reported basis and 6.7% on an organic basis compared to the prior year. GAAP earnings per diluted share were $0.51, compared to $0.38 in the third quarter of 2020, and adjusted earnings per diluted share were $0.86, compared to $0.80 in the prior year.

Integra LifeSciences reported strong second-quarter results, exceeding forecasts with a 50.8% increase in revenues to $390.0 million and adjusted EPS of $0.79. The company is raising its full-year revenue and EPS guidance.

Integra LifeSciences reported a 1.6% increase in reported revenues, reaching $360.1 million, and a GAAP earnings per diluted share of $0.53. The company is raising the lower end of its full-year 2021 revenue guidance by $5 million to a revised range of $1,525 million to $1,535 million and guiding towards the higher end of the full-year 2021 adjusted earnings per share guidance range of $2.86 to $2.93.

Integra LifeSciences reported Q4 2020 revenues of $388.6 million, a decrease of 1.6% compared to Q4 2019. GAAP earnings per diluted share were $1.09, compared to $0.18 in Q4 2019, and adjusted earnings per diluted share were $0.84, compared to $0.68 in Q4 2019.

Integra LifeSciences reported Q3 2020 revenues of $370.2 million, a decrease of 2.3% on a reported basis and 1.5% organically. GAAP EPS was $0.38, compared to a loss of ($0.32) in Q3 2019, while adjusted EPS was $0.80, up from $0.68. The company's full-year 2020 guidance remains withdrawn.

Integra LifeSciences reported a decrease in revenue of 32.6% compared to the prior year, with a GAAP loss per diluted share of ($0.00). The company's full-year 2020 guidance remains withdrawn due to the uncertainty related to COVID-19.

Integra LifeSciences reported a decrease in revenue by 1.5% and a decline in GAAP earnings per diluted share from $0.38 to $0.11 compared to the prior year, largely due to the negative impact of COVID-19 which led to deferral of non-emergent surgical procedures.

Integra LifeSciences reported a 3.1% increase in revenue to $395.1 million and adjusted earnings per diluted share of $0.68 for the fourth quarter of 2019. The company issued its financial guidance for 2020.